Movatterモバイル変換


[0]ホーム

URL:


US20230393088A1 - System and method for optimizing insulin dosages for diabetic subjects - Google Patents

System and method for optimizing insulin dosages for diabetic subjects
Download PDF

Info

Publication number
US20230393088A1
US20230393088A1US18/329,451US202318329451AUS2023393088A1US 20230393088 A1US20230393088 A1US 20230393088A1US 202318329451 AUS202318329451 AUS 202318329451AUS 2023393088 A1US2023393088 A1US 2023393088A1
Authority
US
United States
Prior art keywords
patient
meal
insulin
current
display
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/329,451
Inventor
Robert C. Booth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytec LLC
Original Assignee
Aseko Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aseko IncfiledCriticalAseko Inc
Priority to US18/329,451priorityCriticalpatent/US20230393088A1/en
Assigned to HAYFIN SERVICES LLP, AS THE AGENTreassignmentHAYFIN SERVICES LLP, AS THE AGENTSECURITY INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: Aseko, Inc.
Assigned to BOOTH, ROBERT CreassignmentBOOTH, ROBERT CASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: BOOTH, ROBERT C
Publication of US20230393088A1publicationCriticalpatent/US20230393088A1/en
Assigned to GLYTEC, LLCreassignmentGLYTEC, LLCASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: Aseko, Inc.
Assigned to Aseko, Inc.reassignmentAseko, Inc.CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE FROM BOOTH, ROBERT C TO ASEKO, INC. PREVIOUSLY RECORDED ON REEL 65520 FRAME 324. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.Assignors: BOOTH, ROBERT C.
Pendinglegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

A method and system for optimizing insulin dosages for diabetic subjects which includes a processor for calculating basal and bolus dosages to be recommended for meal types including breakfast, lunch, dinner, snack, or at miscellaneous times. The bolus calculations are specifically directed to time periods which are taken from either pre-meal, post-meal, bedtime, mid-sleep or miscellaneous times. The processor calculates an optimized bolus for a specific time period and meal type based upon prior basal dosages, prior glucose doses, hypoglycemia thresholds, mid-point of target ranges, and subject insulin sensitivity factors. A display is provided to the subject for sensing the optimized insulin dosage recommended at a specific time period and for a specific meal type.

Description

Claims (20)

What is claimed is:
1. A computer-implemented method when executed on data processing hardware causes the data processing hardware to perform operations comprising:
receiving a current glucose measurement of a patient;
determining a glucose time period associated with a time of measuring the current glucose measurement is within a pre-meal time period before the patient consumes food or other nutrients;
determining a meal type associated with the pre-meal time period of the glucose time period is breakfast;
retrieving a previous day basal dose that was administered to the patient and a previous breakfast glucose measurement of the patient from memory hardware;
setting an adjustment factor to a preconfigured adjustment factor associated with a pre-configured range of values that includes the previous breakfast glucose measurement;
calculating a new basal dose of insulin for the patient by multiplying the previous day basal dose times the adjustment factor;
retrieving a configured time interval for administering the calculated new basal dose of insulin to the patient from the memory hardware; and
administering the calculated new basal dose of insulin to the patient by transmitting the calculated dose administering system having a patient display at the configured time interval, the patient display configured to display the calculated new basal dose of insulin.
2. The method ofclaim 1, wherein the operations further comprise:
retrieving a target glucose range for the patient from the memory hardware;
comparing the current glucose measurement to a mid-point of the target glucose range greater than the hypoglycemia threshold; and
determining the current glucose measurement is greater than the mid-point of the target glucose range;
retrieving an insulin sensitivity factor for the patient from the memory hardware;
calculating a correction dose of insulin based on the current glucose measurement, the mid-point of the target glucose range, and the insulin sensitivity factor; and
administering the calculated correction dose of insulin to the patient by transmitting the calculated correction dose to the dose administering system having the patient display configured to display the calculated correction dose of insulin.
3. The method ofclaim 2, wherein the correction dose is calculated as:
CD=(BG-Tm)(1700((Tm-60)×S1×24))
wherein CD is the correction dose of insulin, BG is the current glucose measurement, Tmis the mid-point of the target glucose range, and S1is the insulin sensitivity factor.
4. The method ofclaim 1, wherein the operations further comprise:
retrieving a hypoglycemia threshold from the memory hardware;
comparing the current glucose measurement to the hypoglycemia threshold; and
determining the current glucose measurement is less than the hypoglycemia threshold; and
determining one of:
a recommend dosage of oral glucose for oral ingestion by the patient;
a recommended dosage of glucagon for administration to the patient; or
a recommended dosage of saline and insulin for intravenous insertion to the patient.
5. The method ofclaim 4, wherein the operations further comprise:
receiving a user input, the user input indicating that the consciousness of the patient is not impaired;
determining the recommended dosage of oral glucose for the patient to ingest; and
transmitting the recommended dosage of oral glucose to the patient display, the patient display configured to display the recommended dosage of oral glucose.
6. The method ofclaim 4, wherein the operations further comprise:
receiving a user input, the user input indicating that the consciousness of the patient is impaired;
determining the recommended dosage of glucagon for administration to the patient; and
transmitting the recommended dosage of glucagon to the patient display, the patient display configured to display the recommended dosage of glucagon.
7. The method ofclaim 4, wherein the operations further comprise:
receiving a user input, the user input indicating whether the consciousness of the patient is impaired;
determining the recommended dosage of saline and insulin for intravenous insertion to the patient; and
transmitting the recommended dosage of saline and insulin to the patient display, the patient display configured to display the recommended dosage of saline and insulin.
8. The method ofclaim 1, wherein the operations further comprise:
retrieving a previous meal bolus administered by the patient for the associated meal type from the memory hardware;
setting a meal bolus adjustment factor to a preconfigured meal bolus adjustment factor associated with the pre-configured range of values that includes the current glucose measurement;
calculating a current meal bolus for the patient based on the meal bolus adjustment factor and the previous meal bolus; and
administering the calculated current meal bolus to the patient by transmitting the calculated current meal bolus to the dose administering system having the patient display, the patient display configured to display the calculated current meal bolus.
9. The method ofclaim 8, wherein calculating the current meal bolus comprises:
when the patient is on a fixed meal plan, calculating the current meal bolus by multiplying the previous meal bolus times the meal bolus adjustment factor; or
when the patient is not on a fixed meal plan:
receiving an estimated number of carbohydrates to be ingested by the patient for the associated meal type from the user interface;
obtaining a current carbohydrate to insulin ratio for the associated meal type; and
calculating the current meal bolus by dividing the estimated number of carbohydrates by the current carbohydrate to insulin ratio for the associated meal type.
10. The method ofclaim 9, wherein obtaining the current carbohydrate to insulin ratio for the associated meal type comprises:
retrieving a previous carbohydrate to insulin ratio for the associated meal type from the memory hardware, the previous carbohydrate to insulin ratio associated with the previous meal bolus; and
calculating the current carbohydrate to insulin ratio for the associated meal type by dividing the previous carbohydrate to insulin ratio by the meal bolus adjustment factor.
11. A system comprising:
a glucose measuring device measuring glucose measurements of a patient;
memory hardware; and
data processing hardware in communication with the glucose measuring device and the memory hardware, the data processing processor performing operations comprising:
receiving a current glucose measurement of a patient;
determining a glucose time period associated with a time of measuring the current glucose measurement is within a pre-meal time period before the patient consumes food or other nutrients;
determining a meal type associated with the pre-meal time period of the glucose time period is breakfast;
retrieving a previous day basal dose that was administered to the patient and a previous breakfast glucose measurement of the patient from memory hardware;
setting an adjustment factor to a preconfigured adjustment factor associated with a pre-configured range of values that includes the previous breakfast glucose measurement;
calculating a new basal dose of insulin for the patient by multiplying the previous day basal dose times the adjustment factor;
retrieving a configured time interval for administering the calculated new basal dose of insulin to the patient from the memory hardware; and
administering the calculated new basal dose of insulin to the patient by transmitting the calculated dose administering system having a patient display at the configured time interval, the patient display configured to display the calculated new basal dose of insulin.
12. The system ofclaim 11, wherein the operations further comprise:
retrieving a target glucose range for the patient from the memory hardware;
comparing the current glucose measurement to a mid-point of the target glucose range greater than the hypoglycemia threshold; and
determining the current glucose measurement is greater than the mid-point of the target glucose range;
retrieving an insulin sensitivity factor for the patient from the memory hardware;
calculating a correction dose of insulin based on the current glucose measurement, the mid-point of the target glucose range, and the insulin sensitivity factor; and
administering the calculated correction dose of insulin to the patient by transmitting the calculated correction dose to the dose administering system having the patient display configured to display the calculated correction dose of insulin.
13. The system ofclaim 12, wherein the correction dose is calculated as:
CD=(BG-Tm)(1700((Tm-60)×S1×24))
wherein CD is the correction dose of insulin, BG is the current glucose measurement, Tmis the mid-point of the target glucose range, and S1is the insulin sensitivity factor.
14. The system ofclaim 11, wherein the operations further comprise:
retrieving a hypoglycemia threshold from the memory hardware;
comparing the current glucose measurement to the hypoglycemia threshold; and
determining the current glucose measurement is less than the hypoglycemia threshold; and
determining one of:
a recommend dosage of oral glucose for oral ingestion by the patient;
a recommended dosage of glucagon for administration to the patient; or
a recommended dosage of saline and insulin for intravenous insertion to the patient.
15. The system ofclaim 14, wherein the operations further comprise:
receiving a user input, the user input indicating that the consciousness of the patient is not impaired;
determining the recommended dosage of oral glucose for the patient to ingest; and
transmitting the recommended dosage of oral glucose to the patient display, the patient display configured to display the recommended dosage of oral glucose.
16. The system ofclaim 14, wherein the operations further comprise:
receiving a user input, the user input indicating that the consciousness of the patient is impaired;
determining the recommended dosage of glucagon for administration to the patient; and
transmitting the recommended dosage of glucagon to the patient display, the patient display configured to display the recommended dosage of glucagon.
17. The system ofclaim 14, wherein the operations further comprise:
receiving a user input, the user input indicating whether the consciousness of the patient is impaired;
determining the recommended dosage of saline and insulin for intravenous insertion to the patient; and
transmitting the recommended dosage of saline and insulin to the patient display, the patient display configured to display the recommended dosage of saline and insulin.
18. The system ofclaim 11, wherein the operations further comprise:
retrieving a previous meal bolus administered by the patient for the associated meal type from the memory hardware;
setting a meal bolus adjustment factor to a preconfigured meal bolus adjustment factor associated with the pre-configured range of values that includes the current glucose measurement;
calculating a current meal bolus for the patient based on the meal bolus adjustment factor and the previous meal bolus; and
administering the calculated current meal bolus to the patient by transmitting the calculated current meal bolus to the dose administering system having the patient display, the patient display configured to display the calculated current meal bolus.
19. The system ofclaim 18, wherein calculating the current meal bolus comprises:
when the patient is on a fixed meal plan, calculating the current meal bolus by multiplying the previous meal bolus times the meal bolus adjustment factor; or
when the patient is not on a fixed meal plan:
receiving an estimated number of carbohydrates to be ingested by the patient for the associated meal type from the user interface;
obtaining a current carbohydrate to insulin ratio for the associated meal type; and
calculating the current meal bolus by dividing the estimated number of carbohydrates by the current carbohydrate to insulin ratio for the associated meal type.
20. The method ofclaim 19, wherein obtaining the current carbohydrate to insulin ratio for the associated meal type comprises:
retrieving a previous carbohydrate to insulin ratio for the associated meal type from the memory hardware, the previous carbohydrate to insulin ratio associated with the previous meal bolus; and
calculating the current carbohydrate to insulin ratio for the associated meal type by dividing the previous carbohydrate to insulin ratio by the meal bolus adjustment factor.
US18/329,4512012-09-112023-06-05System and method for optimizing insulin dosages for diabetic subjectsPendingUS20230393088A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US18/329,451US20230393088A1 (en)2012-09-112023-06-05System and method for optimizing insulin dosages for diabetic subjects

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US13/610,287US9897565B1 (en)2012-09-112012-09-11System and method for optimizing insulin dosages for diabetic subjects
US15/862,819US11131643B2 (en)2012-09-112018-01-05Method and system for optimizing insulin dosages for diabetic subjects
US17/474,001US11733196B2 (en)2012-09-112021-09-13System and method for optimizing insulin dosages for diabetic subjects
US18/329,451US20230393088A1 (en)2012-09-112023-06-05System and method for optimizing insulin dosages for diabetic subjects

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US17/474,001ContinuationUS11733196B2 (en)2012-09-112021-09-13System and method for optimizing insulin dosages for diabetic subjects

Publications (1)

Publication NumberPublication Date
US20230393088A1true US20230393088A1 (en)2023-12-07

Family

ID=61188107

Family Applications (4)

Application NumberTitlePriority DateFiling Date
US13/610,287Active2035-03-14US9897565B1 (en)2012-09-112012-09-11System and method for optimizing insulin dosages for diabetic subjects
US15/862,819ActiveUS11131643B2 (en)2012-09-112018-01-05Method and system for optimizing insulin dosages for diabetic subjects
US17/474,001ActiveUS11733196B2 (en)2012-09-112021-09-13System and method for optimizing insulin dosages for diabetic subjects
US18/329,451PendingUS20230393088A1 (en)2012-09-112023-06-05System and method for optimizing insulin dosages for diabetic subjects

Family Applications Before (3)

Application NumberTitlePriority DateFiling Date
US13/610,287Active2035-03-14US9897565B1 (en)2012-09-112012-09-11System and method for optimizing insulin dosages for diabetic subjects
US15/862,819ActiveUS11131643B2 (en)2012-09-112018-01-05Method and system for optimizing insulin dosages for diabetic subjects
US17/474,001ActiveUS11733196B2 (en)2012-09-112021-09-13System and method for optimizing insulin dosages for diabetic subjects

Country Status (1)

CountryLink
US (4)US9897565B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
TW201333870A (en)2011-12-212013-08-16艾登工具股份有限公司Systems and methods for determining insulin therapy for a patient
US10387623B2 (en)*2014-01-282019-08-20Debiotech S.A.Control device with recommendations
EP3500960A1 (en)*2016-08-172019-06-26Novo Nordisk A/SSystems and methods for optimization of bolus timing relative to meal events
EP3928323A1 (en)*2019-02-212021-12-29Companion Medical, Inc.Methods, systems and devices for a medicament dose calculator

Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030028089A1 (en)*2001-07-312003-02-06Galley Paul J.Diabetes management system
US20030208113A1 (en)*2001-07-182003-11-06Mault James RClosed loop glycemic index system
US20060253296A1 (en)*2003-10-292006-11-09Novo Nordisk A/SMedical advisory system
US20070078314A1 (en)*2005-09-302007-04-05Grounsell Richard LSystem and method for measuring and predicting insulin dosing rates
US20070179434A1 (en)*2005-12-082007-08-02Stefan WeinertSystem and method for determining drug administration information
US20090006061A1 (en)*2007-06-272009-01-01Roche Diagnostics Operations, Inc.System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof

Family Cites Families (264)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4055175A (en)1976-05-071977-10-25Miles Laboratories, Inc.Blood glucose control apparatus
FR2387659A1 (en)1977-04-211978-11-17Armines GLYCEMIA CONTROL AND REGULATION DEVICE
US4151845A (en)1977-11-251979-05-01Miles Laboratories, Inc.Blood glucose control apparatus
US4464170A (en)1982-09-291984-08-07Miles Laboratories, Inc.Blood glucose control apparatus and method
US4850959A (en)1988-08-021989-07-25Bioresearch, Inc.Bioelectrochemical modulation of biological functions using resonant/non-resonant fields synergistically
US5101814A (en)1989-08-111992-04-07Palti Yoram ProfSystem for monitoring and controlling blood glucose
US5091190A (en)1989-09-051992-02-25Alza CorporationDelivery system for administration blood-glucose lowering drug
US5251126A (en)1990-10-291993-10-05Miles Inc.Diabetes data analysis and interpretation method
GB9024771D0 (en)1990-11-141991-01-02Axis ResearchAssay
GB9104037D0 (en)1991-02-261991-04-10Hospital For Sick The ChildrenProcess for the phosphorylation of insulin
SE9101381D0 (en)1991-05-071991-05-07Tomas Moks PEPTIDE HORMONE SOLUTION
US5956501A (en)1997-01-101999-09-21Health Hero Network, Inc.Disease simulation system and method
US5917052A (en)1994-09-281999-06-29Shaman Pharmaceuticals, Inc.Hypoglycemic agent from cryptolepis
US5614224A (en)1995-04-201997-03-25Womack; Rick W.Nutritional supplement for diabetics
MY115050A (en)1995-10-162003-03-31Mead Johnson Nutrition CoDiabetic nutritional product having controlled absorption of carbohydrate
US5821217A (en)1995-10-271998-10-13Beth Israel Deaconess Medical Center, Inc.Enteral formulation: low in fat and containing protein hydrolysates
EP0862648B1 (en)1995-11-222004-10-06Medtronic MiniMed, Inc.Detection of biological molecules using chemical amplification and optical sensors
CA2246431A1 (en)1996-01-191997-07-24Board Of Regents, The University Of Texas SystemRecombinant expression of proteins from secretory cell lines
AU718500B2 (en)1997-01-232000-04-13Sumitomo Pharmaceuticals Company, LimitedRemedies for diabetes
US20010002269A1 (en)1997-05-062001-05-31Zhao Iris GinronMulti-phase food & beverage
US6558351B1 (en)1999-06-032003-05-06Medtronic Minimed, Inc.Closed loop system for controlling insulin infusion
US5929055A (en)1997-06-231999-07-27The Research Foundation Of State University Of New YorkTherapeutic method for management of diabetes mellitus
JP2001518316A (en)1997-10-022001-10-16ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Protein delivery by secretory gland expression
CO4970787A1 (en)1997-12-232000-11-07Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
AU5916298A (en)1998-01-091999-07-26Amylin Pharmaceuticals, Inc.Amylin agonist pharmaceutical compositions containing insulin
AU2989699A (en)1998-03-051999-09-20Universal Health-Watch, Inc.Apparatus to non-invasively measure glucose or other constituents in aqueous humor using infra-red spectroscopy
AU748432B2 (en)1998-04-022002-06-06Merck & Co., Inc.Antidiabetic agents
EP1087753A4 (en)1998-05-192004-06-30Sdg IncTargeted liposomal drug delivery system
CN1324234A (en)1998-09-252001-11-28格利科克斯有限公司Fructosamine oxidase: antagonists and inhibitors
US6615081B1 (en)1998-10-262003-09-02Birinder R. BovejaApparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator
CA2352295C (en)1998-11-302008-07-15Novo Nordisk A/SA method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions
US8700161B2 (en)1999-03-052014-04-15Metacure LimitedBlood glucose level control
AU4450700A (en)1999-04-272000-11-10Eli Lilly And CompanyInsulin crystals for pulmonary administration
US6890568B2 (en)1999-05-242005-05-10Grant PierceMethod for management of blood glucose levels
US7806886B2 (en)1999-06-032010-10-05Medtronic Minimed, Inc.Apparatus and method for controlling insulin infusion with state variable feedback
AU5844300A (en)1999-06-042000-12-28Indian Council Of Medical ResearchEugenia jambolina fruit extracts for treating diabetes
AU5453300A (en)1999-06-292001-01-31Eli Lilly And CompanyInsulin crystals for pulmonary administration
CA2381539A1 (en)1999-09-152001-03-22Medtronic Minimed, Inc.Glucose sensing molecules having selected fluorescent properties
DE19954233A1 (en)1999-11-112001-05-31Nutricia Nv Diabetic food
US6572542B1 (en)2000-03-032003-06-03Medtronic, Inc.System and method for monitoring and controlling the glycemic state of a patient
JP4580542B2 (en)2000-05-172010-11-17株式會社バイオニア Microorganism for treating obesity or diabetes and pharmaceutical composition containing the microorganism
WO2001089368A2 (en)2000-05-252001-11-29Healthetech, Inc.Physiological monitoring using wrist-mounted device
US6605039B2 (en)2000-07-242003-08-12Medtronic, Inc.Cell-based biosensors suitable for implantable medical device applications
JP2004505042A (en)2000-08-022004-02-19ファーマニュートリエンツ Methods and compositions for prevention and / or treatment of diabetes and glucose degeneration
US6365176B1 (en)2000-08-082002-04-02Functional Foods, Inc.Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
WO2002036139A1 (en)2000-11-012002-05-10Biovan, Inc.Method for management of blood glucose levels
AU2002251944A1 (en)2001-02-152002-09-04Medtronic Minimed, Inc.Polymers functionalized with fluorescent boronate motifs
ATE419858T1 (en)2001-06-182009-01-15Neptune Technologies & Bioress KRILL EXTRACTS FOR THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR DISEASES
JP3775263B2 (en)2001-08-102006-05-17ニプロ株式会社 Recording medium and blood glucose measurement system using the recording medium
MY135783A (en)2001-09-072008-06-30Meiji Dairies CorpNutritional composition for controlling blood sugar level
WO2003024468A1 (en)2001-09-192003-03-27Bioneer CorporationSubstances extracted from corn which can inhibit the activities of amylase, pharmaceutical compositions and food additives containing the same extracts for treatment or prevention of obesity and diabetes mellitus, and processes for their preparations
WO2003053460A1 (en)2001-12-192003-07-03Eli Lilly And CompanyCrystalline compositions for controlling blood glucose
DK1482919T3 (en)2002-01-252007-07-30Silanes Sa De Cv Lab Pharmaceutical composition for blood sugar control in patients with type 2 diabetes
US20030199445A1 (en)2002-02-072003-10-23Knudsen Lotte BjerreUse of GLP-1 compound for treatment of critically ill patients
TW200304372A (en)2002-03-202003-10-01Kanegafuchi Chemical IndCompositions for diabetes
BRPI0309689B1 (en)2002-04-302021-06-29Unigen, Inc COMPOSITIONS COMPRISING A MIXTURE OF B-RING-FREE FLAVONOIDS AND FLAVANES AND USES THEREOF
JP2003319758A (en)2002-05-072003-11-11Unitika LtdMethod and inhibitor for inhibiting d-glucose absorption
US20040018533A1 (en)2002-06-042004-01-29Adam Gail Isabel ReidDiagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
US20050014158A1 (en)2002-06-272005-01-20Adam Gail Isabel ReidTherapeutic methods for reducing fat deposition and treating associated conditions
KR100709528B1 (en)2002-06-282007-04-20깃세이 야쿠힌 고교 가부시키가이샤 Pharmaceutical composition for blood sugar control
EP1382363A1 (en)2002-07-152004-01-21Novo Nordisk A/SClosed loop system for controlling blood glucose levels
FR2842735B1 (en)2002-07-262006-01-06Flamel Tech Sa MODIFIED RELEASE MICROCAPSULES OF LOW SOLUBLE ACTIVE PRINCIPLES FOR PER OS ADMINISTRATION
US8571801B2 (en)2002-08-282013-10-29Atkins Nutritionals, Inc.Methods and systems for determining and controlling glycemic responses
US20040092590A1 (en)2002-09-272004-05-13Linda ArterburnGlycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
US7504118B2 (en)2003-04-112009-03-17Fhg CorporationDietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
JP2005029570A (en)2003-06-162005-02-03Tokiwa Shokubutsu Kagaku Kenkyusho:KkMethod for production of corosolic acid
US20050054818A1 (en)2003-07-022005-03-10Brader Mark LaurenceCrystalline compositions for controlling blood glucose
US20080119703A1 (en)2006-10-042008-05-22Mark BristerAnalyte sensor
KR100567837B1 (en)2003-10-242006-04-05케이제이헬스케어 주식회사Insulin pump combined with mobile which detects a blood glucose, network system for transmitting control imformation of the insulin pump
US20050096637A1 (en)2003-10-312005-05-05Medtronic, Inc.Sensing food intake
US20080119421A1 (en)2003-10-312008-05-22Jack TuszynskiProcess for treating a biological organism
AU2004285368A1 (en)2003-11-042005-05-12Meiji Dairies CorporationAlpha-glucosidase activity inhibitor
SG179411A1 (en)2003-11-062012-04-27Lifescan IncDrug delivery pen with event notification means
EP1711101A1 (en)2004-01-152006-10-18Glucon Inc.Wearable glucometer
WO2005081171A2 (en)2004-02-192005-09-01Edward Henry MathewsInsulin bolus calculator for mobile communication device
CA2547934C (en)2004-02-192013-05-21Abbott LaboratoriesMethods of using gamma cyclodextrin to control blood glucose and insulin secretion
WO2005081173A1 (en)2004-02-192005-09-01Edward Henry MathewsDiabetes slide ruler for blood glucose control
WO2005081119A2 (en)2004-02-192005-09-01Edward Henry MathewsInteractive diabetes education system
WO2005081170A2 (en)2004-02-192005-09-01Edward Henry MathewsDiabetes management and patient database system via mobile communication device
WO2006006286A1 (en)2004-07-092006-01-19Meiji Dairies CorporationComposition for enhancing the production of ppar and/or ppar-associated factor
WO2006022638A1 (en)2004-07-222006-03-02Sequenom, Inc.Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022619A2 (en)2004-07-222006-03-02Sequenom, Inc.Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022629A1 (en)2004-07-222006-03-02Sequenom, Inc.Methods of identifying risk of type ii diabetes and treatments thereof
WO2006022633A1 (en)2004-07-222006-03-02Sequenom, Inc.Methods for identifying a risk of type ii diabetes and treatments thereof
WO2006022636A1 (en)2004-07-222006-03-02Sequenom, Inc.Methods for identifying risk of type ii diabetes and treatments thereof
US20080199480A1 (en)2004-07-222008-08-21Sequenom, Inc.Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
WO2006022634A1 (en)2004-07-222006-03-02Sequenom, Inc.Methods for identifying risk of type ii diabetes and treatments thereof
US20070060549A1 (en)2004-08-102007-03-15Friesen Albert DCombination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060040003A1 (en)2004-08-102006-02-23Alvin NeedlemanDietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free
US20060046962A1 (en)2004-08-252006-03-02Aegis Therapeutics LlcAbsorption enhancers for drug administration
US20120213886A1 (en)2004-08-252012-08-23U.S. Dept. Of Veterans AffairsCompositions and Methods to Lower Glycohemoglobin Levels
EP1698898A3 (en)2004-09-212006-10-11Foundation of Biomedical Research of the Academy of AthensPrognostic, diagnostic and therapeutic significance in detecting and using TIN-antigen (Tubulo-Interstitial nephritis antigen) and its segments
US20060078593A1 (en)2004-09-272006-04-13Strozier Deborah CNutritional compostions comprising a soluble viscous fiber in a solid crisp matrix
WO2006044556A2 (en)2004-10-142006-04-27Galileo Pharmaceuticals, Inc.Dual inhibitors of lipoxygenase for treating diabetes
US8117020B2 (en)2004-12-032012-02-14Roche Diagnostics Operations, Inc.Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via creation and continuous updating of new statistical indicators
ITMI20050010A1 (en)2005-01-052006-07-06Aboca S P A NUTRACEUTICAL PHARMACEUTICAL COMPOSITIONS NUTRITIONAL DIETS BASED ON VEGETABLE FIBERS
CA2491763A1 (en)2005-01-062006-07-06Tassos P. AnastassiadesBlood glucose control with n-acylated glucosamines
WO2006079124A2 (en)2005-01-242006-07-27Edward Henry MathewsApparatus and method for predicting the effect of ingested foodstuff or exercise on blood sugar level of patient and suggesting a corrective action
WO2006091918A2 (en)2005-02-232006-08-31Streck, Inc.Process, composition and kit for providing a stable whole blood calibrator/control
US20060188995A1 (en)2005-02-242006-08-24Ryan Wayne LProcess, composition and kit for providing a stable whole blood calibrator/control
KR100750988B1 (en)2005-03-182007-08-22주식회사 유니젠 Pharmaceutical composition for the prevention or treatment of diabetes or glycemic control abnormalities, including ginsenoside derived from natural products
BRPI0500959A (en)2005-03-232006-11-21Unicamp pharmacological use of peroxisome proliferator-activated receptor (pgc-1 (alpha)) coactivating protein 1 alpha expression inhibitor for the treatment of diabetes mellitus, insulin resistance and metabolic syndrome, its compound and its composition
RU2007143510A (en)2005-04-272009-06-10Яллал МЕССАДЕК (BE) INSULIN COMPOSITIONS
US20060263450A1 (en)2005-05-172006-11-23Julius ObenMethod and composition for reducing body weight and improving control of body lipids
US7509156B2 (en)2005-05-182009-03-24Clarian Health Partners, Inc.System for managing glucose levels in patients with diabetes or hyperglycemia
WO2006130901A1 (en)2005-06-072006-12-14Bayer Healthcare AgControl of metabolic abnormalities
US20090239944A1 (en)2005-06-242009-09-24D Orazio DanielNovel Use of Organic Compounds
BRPI0614489A2 (en)2005-08-012011-03-29Mannkind Corp method for preserving the function of insulin producing cells
US7704226B2 (en)2005-11-172010-04-27Medtronic Minimed, Inc.External infusion device with programmable capabilities to time-shift basal insulin and method of using the same
US8557274B2 (en)2005-12-062013-10-15Purdue Research FoundationSlowly digesting starch and fermentable fiber
US8057840B2 (en)2006-01-252011-11-15Tate & Lyle Ingredients Americas LlcFood products comprising a slowly digestible or digestion resistant carbohydrate composition
US7824333B2 (en)2006-03-312010-11-02Lifescan, Inc.Diabetes management methods and systems
US20070282186A1 (en)2006-05-022007-12-06Adrian GilmoreBlood glucose monitor with an integrated data management system
US8548544B2 (en)2006-06-192013-10-01Dose SafetySystem, method and article for controlling the dispensing of insulin
CA2655566A1 (en)2006-06-302008-01-10Healthy Interactions, Inc.System, method, and device for providing health information
KR101080955B1 (en)2006-07-142011-11-08포항공과대학교 산학협력단Epidermal growth factor increases insulin secretion and lowers blood glucose
WO2008013324A1 (en)2006-07-282008-01-31National University Corporation Kanazawa UniversityUse of diabetes-related, liver-derived secreted protein in diagnosis or treatment of type-2 diabetes or vascular disorder
WO2008073609A2 (en)2006-11-012008-06-19Philip Michael SherDevice for predicting and managing blood glucose concentration by analyzing the effect of, and controlling, pharmacodynamic insulin unit equivalents
US20080139910A1 (en)2006-12-062008-06-12Metronic Minimed, Inc.Analyte sensor and method of using the same
US7946985B2 (en)2006-12-292011-05-24Medtronic Minimed, Inc.Method and system for providing sensor redundancy
WO2008124478A1 (en)2007-04-042008-10-16Pronia Medical Systems, LlcSystems, methods, and computer program product for improved management of medical procedures for patients on medical protocols
CA2684457A1 (en)2007-04-192008-10-30C.G.M.3 LtdDevice system and method for monitoring and controlling blood analyte levels
US8417311B2 (en)2008-09-122013-04-09Optiscan Biomedical CorporationFluid component analysis system and method for glucose monitoring and control
EP2178546A1 (en)2007-08-212010-04-28ATP Marketing & Promotion AGHerbal formulations for controlling blood glucose levels in patients with diabetes
US7943163B2 (en)2007-08-222011-05-17Response Scientific, Inc.Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
TWI348910B (en)2007-10-292011-09-21Univ Taipei MedicalComposition for controlling blood glucose and method thereof
WO2009081403A2 (en)2007-12-262009-07-02Medingo Ltd.Maintaining glycemic control during exercise
US20090177147A1 (en)2008-01-072009-07-09Michael BlomquistInsulin pump with insulin therapy coaching
US20090238879A1 (en)2008-01-242009-09-24Northwestern UniversityDelivery scaffolds and related methods of use
US20090214511A1 (en)2008-02-212009-08-27Trung Hong TranDigestible compositions of inulin for managing blood glucose levels
US8317699B2 (en)2008-02-292012-11-27Roche Diagnostics Operations, Inc.Device and method for assessing blood glucose control
US8396528B2 (en)2008-03-252013-03-12Dexcom, Inc.Analyte sensor
US20090242399A1 (en)2008-03-252009-10-01Dexcom, Inc.Analyte sensor
US8185412B1 (en)2008-03-282012-05-22Mahesh HarpaleMethod and apparatus for chronic care treatment control with custom named-type factors and user estimation error correction
WO2009124111A2 (en)2008-04-012009-10-08Trustees Of Boston UniversityGlucose sensor employing semiconductor nanoelectronic device
ES2670793T3 (en)2008-04-042018-06-01Hygieia, Inc. Apparatus for optimizing an insulin dosage regimen for a patient
TWI394580B (en)2008-04-282013-05-01Halozyme IncSuper fast-acting insulin compositions
BRPI0822909B8 (en)2008-06-262021-05-25Laboratorios Silanes S A De C V metformin glycinate salt for blood glucose control
IT1396465B1 (en)2008-07-102012-12-14B G Informatica S R L METHOD FOR THE DEFINITION AND INTERACTIVE MANAGEMENT OF A TREATMENT FOR THE CONTROL OF GLYCEMIC RATE IN THE DIABETIC PATIENT AND INTEGRATED DEVICE THAT IMPLEMENTS THIS METHOD
KR100918776B1 (en)2009-04-202009-09-24계명대학교 산학협력단 Blood Glucose Inhibition Composition Using Polyethylene Glycol and Gallate Catechin
EP2352456A1 (en)2008-08-202011-08-10Bayer HealthCare LLCHealth management supply organizing system and methods
US20110177175A1 (en)2008-09-232011-07-21Rubicon Research Private LimitedDietary fiber compositions
EP2179661A1 (en)2008-10-232010-04-28Generale BiscuitBiscuit comprising guar gum in a rod-like form
WO2010056718A2 (en)2008-11-112010-05-20Hygieia, Inc.Apparatus and system for diabetes management
US8527208B2 (en)2008-11-172013-09-03Roche Diagnostics International AgPrandial blood glucose excursion optimization method via computation of time-varying optimal insulin profiles and system thereof
US20120011125A1 (en)2008-12-232012-01-12Roche Diagnostics Operations, Inc.Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8198320B2 (en)2008-12-312012-06-12Taipei Medical UniversityHypoglycemic activity of osthole
WO2010078842A1 (en)2009-01-072010-07-15Huang HaidongGene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
US20120053222A1 (en)2009-01-232012-03-01Mark GorrellNovel Metabolic Disease Therapy
AU2010236680A1 (en)2009-04-142011-11-10Abbott LaboratoriesHigh fiber nutritional emulsions for blood glucose control
WO2010129375A1 (en)2009-04-282010-11-11Abbott Diabetes Care Inc.Closed loop blood glucose control algorithm analysis
GB2471066A (en)2009-06-102010-12-22Dna Electronics LtdA glucagon pump controller
US9218453B2 (en)2009-06-292015-12-22Roche Diabetes Care, Inc.Blood glucose management and interface systems and methods
CN102018766B (en)2009-09-162013-03-06博仲盛景医药技术(北京)有限公司Plant extractive, extraction method and application thereof as well as composite comprising same
KR101632308B1 (en)2009-09-232016-06-21삼성전자주식회사Method and apparatus for providing blood glucose management information
EP2644088B1 (en)2009-09-292017-01-18Lifescan Scotland LimitedAnalyte testing method and device for diabetes management
KR20120102048A (en)*2009-09-302012-09-17모르 리서치 애플리케이션즈 리미티드Monitoring device for management of insulin delivery
US20110098548A1 (en)2009-10-222011-04-28Abbott Diabetes Care Inc.Methods for modeling insulin therapy requirements
US20110115894A1 (en)2009-11-192011-05-19Daniel Rogers BurnettDevice and method for diagnosis and monitoring of neural, opthalmologic and retinal disorders
WO2011073788A2 (en)2009-12-182011-06-23Dr Reddy's Laboratories, LimitedBalaglitazone compositions and methods
US8759284B2 (en)2009-12-242014-06-24Rani Therapeutics, LlcTherapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20110173308A1 (en)2010-01-142011-07-14Brent GutekunstSystem and method for medical surveillance through personal communication device
AR080029A1 (en)2010-01-272012-03-07Baylor Res Inst COMPOSITION OF MICROBUBBLES THAT INCLUDES A PLASMIDIC DNA CODIFYING A GROWTH FACTOR OF THE HUMAN VASCULAR ENDOTHELY
US8579879B2 (en)2010-02-192013-11-12Medtronic Minimed, Inc.Closed-loop glucose control startup
US9089292B2 (en)2010-03-262015-07-28Medtronic Minimed, Inc.Calibration of glucose monitoring sensor and/or insulin delivery system
US9144586B2 (en)2010-04-072015-09-29Incube Labs, LlcMethod for treating glucose related disorders using stem cell-derived gastro-intestinal cells
US20120197358A1 (en)2010-04-092012-08-02Prescott Marvin ALight Therapy for Treating or Managing Diabetes and Metabolic Syndrome
JP2011237408A (en)2010-04-142011-11-24Arkray IncBiological information measuring device, lighting method in the same and biological information measuring method
US9387279B2 (en)2010-05-052016-07-12The Governing Council Of The University Of TorontoImplantable-glucose responsive insulin delivery device
US10561785B2 (en)2010-06-222020-02-18Medtronic Minimed, Inc.Method and/or system for closed-loop control of glucose to a treatment range
US8543354B2 (en)2010-06-232013-09-24Medtronic Minimed, Inc.Glucose sensor signal stability analysis
US20120003339A1 (en)2010-07-022012-01-05Minacapelli PompeoCompositions and methods for controlling blood glucose levels
US20120006100A1 (en)2010-07-062012-01-12Medtronic Minimed, Inc.Method and/or system for determining blood glucose reference sample times
US8828390B2 (en)2010-07-092014-09-09Universitat ZurichUses of NOGO-A inhibitors and related methods
US8870807B2 (en)2010-07-192014-10-28Surag MantriGastro-intestinal compression device
WO2012010298A1 (en)2010-07-232012-01-26Roche Diagnostics GmbhSystem and method considering the effect of physical activity on the glucoregulatory system
AU2011280986B2 (en)2010-07-232015-11-12Avacen, Inc.Methods and apparatus for therapeutic application of thermal energy
EP2603133A1 (en)2010-08-102013-06-19Roche Diagnostics GmbHMethod and system for improving glycemic control
US20120100248A1 (en)2010-08-172012-04-26Abbott LaboratoriesNutritional composition comprising cereal beta-glucan and salacia extract
US20120058942A1 (en)2010-09-032012-03-08John DupreMethods for controlling blood-glucose levels in insulin-requiring subjects
WO2012047800A1 (en)2010-10-062012-04-12Abbott LaboratoriesMethods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend
US20130225683A1 (en)2010-10-272013-08-29Prometic Biosciences Inc.Compounds and Pharmaceutical Compositions for Uses in Diabetes
US8919180B2 (en)2010-10-282014-12-30Medtronic Minimed, Inc.Determination and application of glucose sensor reliability indicator and/or metric
US8657746B2 (en)2010-10-282014-02-25Medtronic Minimed, Inc.Glucose sensor signal purity analysis
WO2012058694A2 (en)2010-10-312012-05-03Trustees Of Boston UniversityBlood glucose control system
US8349612B2 (en)2010-11-152013-01-08Roche Diagnostics Operations, Inc.Guided structured testing kit
EP2640373A4 (en)2010-11-162014-04-23Univ New Jersey Med TREATMENT OF TYPE II DIABETES AND DISEASES ASSOCIATED WITH DIABETES THROUGH SAFE CHEMICAL MITOCHONDRIAL DECOUPLERS
US20120295985A1 (en)2010-11-192012-11-22Miller Guy MMethods for improving blood glucose control
CN102462736B (en)2010-11-192015-07-15北京唐安营养保健品有限公司Preparation method of cinnamon water extract
US8329232B2 (en)2010-11-232012-12-11Beijing Tang-An Nutrition & Healthcare Products Co. Ltd.Process for preparing water extract of cinnamon
ES2396844B1 (en)2010-12-012014-01-27Universitat Politècnica De Catalunya System and method for simultaneous and non-invasive estimation of blood glucose, glucocorticoid level and blood pressure
US9238802B2 (en)2010-12-012016-01-19Kikkoman CorporationE. coli transformant, method for producing flavin-bound glucose dehydrogenase using the same, and mutant flavin-bound glucose dehydrogenases
US9469844B2 (en)2010-12-022016-10-18Kikkoman CorporationFlavin-bound glucose dehydrogenases, a method for producing a flavin-bound glucose dehydrogenase, and yeast transformant used for the same
EP2654777A4 (en)2010-12-212014-07-09Nestec Sa METHODS AND COMPOSITIONS SUITABLE FOR MANAGING GLYCEMIA IN ANIMALS
US20120173151A1 (en)2010-12-292012-07-05Roche Diagnostics Operations, Inc.Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
WO2012097064A1 (en)2011-01-132012-07-19Abbott LaboratoriesNutritional compositions and methods for controlling blood glucose
MX350611B (en)2011-01-312017-09-11Cadila Healthcare LtdTreatment for lipodystrophy.
CN107019515B (en)*2011-02-282021-02-26雅培糖尿病护理公司Method of displaying sensor readings and analyte monitoring device and method of operating the same
EP2685895B1 (en)2011-03-172018-10-10University of Newcastle Upon TyneSystem for the self-monitoring and regulation of blood glucose
MX339374B (en)2011-04-292016-05-13Inst De Investigación En Química Aplic S A De C VMetformin-based ionic co-crystals.
US8690934B2 (en)2011-05-092014-04-08The Invention Science Fund I, LlcMethod, device and system for modulating an activity of brown adipose tissue in a vertebrate subject
US8755938B2 (en)2011-05-132014-06-17Roche Diagnostics Operations, Inc.Systems and methods for handling unacceptable values in structured collection protocols
US8766803B2 (en)2011-05-132014-07-01Roche Diagnostics Operations, Inc.Dynamic data collection
EP3293197B1 (en)2011-06-072020-01-08Wisconsin Alumini Research FoundationHepatocyte based insulin gene therapy for diabetes
JP5890516B2 (en)2011-06-172016-03-22ハロザイム インコーポレイテッド Continuous subcutaneous insulin infusion method using hyaluronan degrading enzyme
WO2012178134A2 (en)2011-06-232012-12-27University Of Virginia Patent FoundationUnified platform for monitoring and control of blood glucose levels in diabetic patients
KR20140082642A (en)2011-07-262014-07-02글리젠스 인코포레이티드Tissue implantable sensor with hermetically sealed housing
US8667293B2 (en)2011-08-112014-03-04Roche Diagnostics Operations, Inc.Cryptographic data distribution and revocation for handheld medical devices
GB2493712B (en)2011-08-122014-07-02Gene Onyx LtdInsulin pump
JP2014524297A (en)2011-08-182014-09-22ノボ・ノルデイスク・エー/エス Drug delivery device having means for handling data
WO2013040712A1 (en)2011-09-202013-03-28Afexa Life Sciences Inc.Composition comprising ku ding cha and ginseng for managing blood glucose levels
WO2013049381A1 (en)2011-09-282013-04-04Abbott Diabetes Care Inc.Methods for analyte monitoring management and analyte measurement data management, and articles of manufacture related thereto
US20130085682A1 (en)2011-10-042013-04-04Roche Diagnostics Operations, Inc.Memory card usage with blood glucose devices
EP2763722B1 (en)2011-10-072016-08-10Novo Nordisk A/SSystem for determining position of element based on three-axial magnetic sensors
US20130144283A1 (en)2011-12-022013-06-06Medtronic Ardian Luxembourg S.A.R.L.Treatment of polycystic ovary syndrome using renal neuromodulation and associated systems and methods
US20140315162A1 (en)2011-12-092014-10-23Joel EhrenkranzSystem and methods for monitoring food consumption
JP2015503565A (en)2011-12-292015-02-02ラティチュード ファーマシューティカルズ インコーポレイテッドLatitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsion
US20130172688A1 (en)2011-12-292013-07-04Roche Diagnostics Operations, Inc.Diabetes management application for mobile phone
WO2013108262A1 (en)2012-01-182013-07-25Zota Health Care LtdSynergistic combination for the treatment of diabetic neuropathy
US10694983B2 (en)2012-01-192020-06-30Medtronic Minimed, Inc.Method and/or system for assessing a patient's glycemic response
WO2013108122A1 (en)2012-01-202013-07-25Mueller-Wolf Martin"indima apparatus" system, method and computer program product for individualized and collaborative health care
KR101166907B1 (en)2012-02-082012-07-19최병철The extract of rhynchosia volubilis and its manufacturing method bearing the character of bioactivity such as blood sugar
EP2812706A1 (en)2012-02-102014-12-17Alere Switzerland GmbHAssay and method for determining insulin-resistance
US9010477B2 (en)2012-02-162015-04-21Aonec, LlcIn vehicle glucose apparatus and vehicular operation inhibitor
ES2421956B1 (en)2012-03-022014-09-29Moehs Ibérica S.L. NEW CRYSTAL FORM OF SITAGLIPTINA SULFATE
US9080939B2 (en)2012-03-062015-07-14National Central UniversityMethod of measuring glycosylated protein proportion by AC impedance method
WO2013134469A1 (en)2012-03-072013-09-12Medtronic Ardian Luxembourg SarlSelective modulation of renal nerves
AU2013230781B2 (en)2012-03-082015-12-03Medtronic Af Luxembourg S.A.R.L.Ovarian neuromodulation and associated systems and methods
US20140337041A1 (en)2012-03-302014-11-13Joseph MaddenMobile Application for Defining, Sharing and Rewarding Compliance with a Blood Glucose Level Monitoring Regimen
US20130281796A1 (en)2012-04-202013-10-24Broadmaster Biotech Corp.Biosensor with exercise amount measuring function and remote medical system thereof
PH12013500989B1 (en)2012-05-162019-10-16Melaleuca IncDietary supplement compositions
US20150174209A1 (en)2012-05-252015-06-25Amylin Pharmaceuticals. LlcInsulin-pramlintide compositions and methods for making and using them
US20130317316A1 (en)2012-05-252013-11-28City Of HopeCarbohydrate modeling methods, systems, and devices
US9150482B2 (en)2012-06-062015-10-06Development Center For BiotechnologyGLP-1 potentiators from hedychium coronarium and their applications
US9536449B2 (en)2013-05-232017-01-03Medibotics LlcSmart watch and food utensil for monitoring food consumption
US9254099B2 (en)2013-05-232016-02-09Medibotics LlcSmart watch and food-imaging member for monitoring food consumption
US9861744B2 (en)2012-06-252018-01-09International Business Machines CorporationManaging blood glucose levels
US20140012118A1 (en)2012-07-092014-01-09Dexcom, Inc.Systems and methods for leveraging smartphone features in continuous glucose monitoring
US8492426B1 (en)2012-07-122013-07-23Anis AhmadUse of carvedilol for treatment of diabetes mellitus
WO2014024201A1 (en)2012-08-062014-02-13Ramchandran T SRegulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor
AR092077A1 (en)2012-08-102015-03-18Sanofi Aventis Deutschland MEDICAL SYSTEM
WO2014028607A1 (en)2012-08-142014-02-20Abbott LaboratoriesLow glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9504411B2 (en)2012-08-282016-11-29Roche Diabetes Care, Inc.Diabetes manager for glucose testing and continuous glucose monitoring
US9662445B2 (en)2012-08-302017-05-30Medtronic Minimed, Inc.Regulating entry into a closed-loop operating mode of an insulin infusion system
US9171343B1 (en)*2012-09-112015-10-27Aseko, Inc.Means and method for improved glycemic control for diabetic patients
US9278200B2 (en)2012-09-192016-03-08Mackay Memorial HospitalFlow control device, system and method for controlling the flow of body fluid
EP2727587A1 (en)2012-10-302014-05-07PharnextCompositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
PE20151518A1 (en)2012-11-132015-11-25Gordagen Pharmaceuticals Pty Ltd TRANSMUCOSE ADMINISTRATION OF TOCOTRIENOL
US9744211B2 (en)2012-12-172017-08-29MYGALAXY Limited CompanyUses of BT lipopeptides as therapeutics for obesity and related diseases
US9351670B2 (en)2012-12-312016-05-31Abbott Diabetes Care Inc.Glycemic risk determination based on variability of glucose levels
US9192509B2 (en)2013-03-112015-11-24Avacen, Inc.Methods and apparatus for therapeutic application of thermal energy including blood viscosity adjustment
WO2014149781A1 (en)2013-03-152014-09-25Cercacor Laboratories, Inc.Cloud-based physiological monitoring system
US9795737B2 (en)2013-03-152017-10-24Animas CorporationMethod and system for closed-loop control of an artificial pancreas
CN105377118B (en)2013-03-152019-09-17雅培糖尿病护理公司 Devices, systems and methods associated with analyte monitoring devices and devices incorporating the same
EP2967506B1 (en)2013-03-152020-04-29Becton, Dickinson and CompanySmart adapter for infusion devices
WO2014162549A1 (en)2013-04-042014-10-09テルモ株式会社Blood glucose management system
US9237866B2 (en)2013-04-292016-01-19Birch Narrows Development, LLCBlood glucose management
US20160089500A1 (en)2013-05-212016-03-31Novo Nordisk A/SDrug Delivery Device with Means for Disabling Activation of Expelling Mechanism
CA2913334A1 (en)2013-05-232014-11-27Iphenotype LlcMethod and system for maintaining or improving wellness
US9529385B2 (en)2013-05-232016-12-27Medibotics LlcSmart watch and human-to-computer interface for monitoring food consumption
US9056049B2 (en)2013-05-302015-06-16Chin Yuan HuangMicro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels
CN103432572B (en)2013-06-212018-09-18四川大学华西医院Preparation method of rhesus monkey diabetic nephropathy model
US9482635B2 (en)2013-06-252016-11-01Animas CorporationGlucose-measurement systems and methods presenting icons
WO2014209630A2 (en)2013-06-272014-12-31Inspark Technologies, Inc.Systems, devices, and/or methods for identifying time periods of insufficient blood glucose testing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030208113A1 (en)*2001-07-182003-11-06Mault James RClosed loop glycemic index system
US20030028089A1 (en)*2001-07-312003-02-06Galley Paul J.Diabetes management system
US20060253296A1 (en)*2003-10-292006-11-09Novo Nordisk A/SMedical advisory system
US20070078314A1 (en)*2005-09-302007-04-05Grounsell Richard LSystem and method for measuring and predicting insulin dosing rates
US20070179434A1 (en)*2005-12-082007-08-02Stefan WeinertSystem and method for determining drug administration information
US20090006061A1 (en)*2007-06-272009-01-01Roche Diagnostics Operations, Inc.System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Davidson et al. (Diabetes Care, 2005, Vol. 28, No. 10, pp.2418-23) (Year: 2005)*
Kaufman et al. (Diabetes Metab. Res. Rev., 1999, Vol. 15, p.338-352). (Year: 1999)*
Steil et al. (Diabetes, 2006, Vol. 55, pp.3344-3350) (Year: 2006)*

Also Published As

Publication numberPublication date
US20220074883A1 (en)2022-03-10
US11131643B2 (en)2021-09-28
US20180128765A1 (en)2018-05-10
US11733196B2 (en)2023-08-22
US9897565B1 (en)2018-02-20

Similar Documents

PublicationPublication DateTitle
US11733196B2 (en)System and method for optimizing insulin dosages for diabetic subjects
US10629294B2 (en)Means and method for improved glycemic control for diabetic patients
CN110869075B (en)Calculation of residual insulin Activity content in Artificial islet systems
JP3594897B2 (en) Extrapolation system for glucose concentration
US6582366B1 (en)Medical devices for contemporaneous decision support in metabolic control
US9486172B2 (en)Estimation of insulin sensitivity from CGM and subcutaneous insulin delivery in type 1 diabetes
US8454510B2 (en)Method and device for assessing carbohydrate-to-insulin ratio
Magdelaine et al.A long-term model of the glucose–insulin dynamics of type 1 diabetes
US6544212B2 (en)Diabetes management system
CN102596307B (en)Utilize nominal open loop characteristic in diabetes, carry out system, the method and computer program product of insulin feed adjustment (AID)
US20200015760A1 (en)Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems
WO2016061308A1 (en)Human metabolic condition management
Hussain et al.Insulin Pumps and Continuous Glucose Monitoring Made Easy E-Book: Insulin Pumps and Continuous Glucose Monitoring Made Easy E-Book
US9652595B1 (en)Kit that improves impaired hepatic glucose processing in subjects
US10533990B2 (en)Physiologic insulin-sensitivity improvement
Bhat et al.Automated glucose control: A review
Reiterer et al.Identification of mixed-meal effects on insulin needs and glycemic control
EP4120281A1 (en)Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems
Hu et al.Type 1 Diabetes in Children and Adolescents
KleckThe Efficacy of a Bi-hormonal Closed-loop System at Preventing Hypoglycemia during and after Exercise
RoncaEstimation of insulin sensitivity from continuous glucose monitoring and insulin pump data in type 1 diabetes

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:HAYFIN SERVICES LLP, AS THE AGENT, UNITED KINGDOM

Free format text:SECURITY INTEREST;ASSIGNOR:ASEKO, INC.;REEL/FRAME:064517/0872

Effective date:20230804

ASAssignment

Owner name:BOOTH, ROBERT C, MASSACHUSETTS

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOOTH, ROBERT C;REEL/FRAME:065520/0324

Effective date:20120911

STPPInformation on status: patent application and granting procedure in general

Free format text:NON FINAL ACTION MAILED

STPPInformation on status: patent application and granting procedure in general

Free format text:RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

ASAssignment

Owner name:GLYTEC, LLC, MASSACHUSETTS

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASEKO, INC.;REEL/FRAME:067320/0764

Effective date:20240228

Owner name:ASEKO, INC., SOUTH CAROLINA

Free format text:CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE FROM BOOTH, ROBERT C TO ASEKO, INC. PREVIOUSLY RECORDED ON REEL 65520 FRAME 324. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:BOOTH, ROBERT C.;REEL/FRAME:066975/0110

Effective date:20120911

STPPInformation on status: patent application and granting procedure in general

Free format text:FINAL REJECTION MAILED

STPPInformation on status: patent application and granting procedure in general

Free format text:RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPPInformation on status: patent application and granting procedure in general

Free format text:ADVISORY ACTION MAILED

STPPInformation on status: patent application and granting procedure in general

Free format text:DOCKETED NEW CASE - READY FOR EXAMINATION

STPPInformation on status: patent application and granting procedure in general

Free format text:NON FINAL ACTION MAILED

STPPInformation on status: patent application and granting procedure in general

Free format text:RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPPInformation on status: patent application and granting procedure in general

Free format text:NON FINAL ACTION MAILED

STPPInformation on status: patent application and granting procedure in general

Free format text:RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER


[8]ページ先頭

©2009-2025 Movatter.jp